Click here to close
Hello! We notice that you are using Internet Explorer, which is not supported by Xenbase and may cause the site to display incorrectly.
We suggest using a current version of Chrome,
FireFox, or Safari.
Drug Des Devel Ther
2014 Nov 07;8:2263-71. doi: 10.2147/DDDT.S70461.
Show Gene links
Show Anatomy links
Inhibition of cardiac Kv1.5 potassium current by the anesthetic midazolam: mode of action.
Vonderlin N
,
Fischer F
,
Zitron E
,
Seyler C
,
Scherer D
,
Thomas D
,
Katus HA
,
Scholz EP
.
???displayArticle.abstract???
Midazolam is a short-acting benzodiazepine that is widely used in anesthesia. Despite its widespread clinical use, detailed information about cardiac side effects of midazolam is largely lacking. Using the double-electrode voltage clamp technique, we studied pharmacological effects of midazolam on heterologously expressed Kv1.5 channels underlying atrial repolarizing current I(Kur). Midazolam dose-dependently inhibited Kv1.5 current, yielding an IC50 of 17 μM in an HEK cell line and an IC50 of 104 μM in Xenopus oocytes. We further showed that midazolam did not affect the half-maximal activation voltage of Kv1.5 channels. However, a small negative shift of the inactivation curve could be observed. Midazolam acted as a typical open-channel inhibitor with rapid onset of block and without frequency dependence of block. Taken together, midazolam is an open channel inhibitor of cardiac Kv1.5 channels. These data add to the current understanding of the pharmacological profile of midazolam.
Figure 1. Midazolam inhibits cloned cardiac Kv1.5 potassium channels.Notes: (A) Representative current trace of a typical Kv1.5 current elicited by a rectangular voltage protocol in Xenopus oocytes. Midazolam (100 μM) results in a strong inhibition of Kv1.5 current. (B) Dose–response curves for inhibition of Kv1.5 by midazolam established in Xenopus oocytes. (C) Representative current trace of a typical Kv1.5 current elicited by a rectangular voltage protocol in an HEK cell line using the patch-clamp technique. Midazolam (30 μM) results in a pronounced reduction of Kv1.5 current. (D) Dose–response curves established in an HEK cell line stably expressing Kv1.5 channels.
Figure 2. Pharmacological properties of Kv1.5 current inhibition.Notes: Typical families of Kv1.5 current traces elicited by a double-step voltage protocol (inset in [A]) before (A) and after (B) incubation with 100 μM midazolam in Xenopus oocytes. (C) Current–voltage relationship of Kv1.5 current under control conditions (filled boxes) and after incubation with midazolam (open circles) measured at peak current (n=6). (D) Kv1.5 activation curves established by dividing peak current amplitude by the electrochemical driving force. Midazolam did not significantly influence the half-maximal activation voltage (V1/2) (n=6). (E) Kv1.5 channel inactivation curves established by plotting tail current amplitude versus the potential of the first voltage step. Midazolam resulted in a small but significant shift of the inactivation curve (n=6).
Figure 3. Time constants of channel inhibition.Notes: Exemplary current traces elicited by a rectangular voltage step to +50 mV under control conditions and after application of 30 μM (A) or 1,000 μM (B) midazolam in Xenopus oocytes. Time course of block development was determined by division. In both cases, development of block was fast, yielding time constants (τ) of 9.0 ms for 30 μM (C) and 4.1 ms for 1,000 μM (D) midazolam.
Figure 4. Frequency dependence of Kv1.5 channel block.Notes: Frequency dependence of block was analyzed in Xenopus oocytes using three different pacing rates (1 Hz, 2 Hz, and 4 Hz). Having obtained a control measurement, 300 μM midazolam was washed-in and the measurement was repeated. (A–C) Exemplary experiments showing the first (t=0 seconds) and last (t=16 seconds) current traces after application of 300 μM midazolam. (D) The degree of inhibition was calculated for the last test pulse (at 16 seconds), yielding no significant dependence on the pacing rate (n=6).Abbreviations: t, time; s, seconds.
Buljubasic,
Differential effects of etomidate, propofol, and midazolam on calcium and potassium channel currents in canine myocardial cells.
1996, Pubmed
Buljubasic,
Differential effects of etomidate, propofol, and midazolam on calcium and potassium channel currents in canine myocardial cells.
1996,
Pubmed
Crevat-Pisano,
Plasma concentrations and pharmacokinetics of midazolam during anaesthesia.
1986,
Pubmed
Decher,
Molecular basis for Kv1.5 channel block: conservation of drug binding sites among voltage-gated K+ channels.
2004,
Pubmed
,
Xenbase
Decher,
Binding site of a novel Kv1.5 blocker: a "foot in the door" against atrial fibrillation.
2006,
Pubmed
,
Xenbase
Dundee,
Midazolam. A review of its pharmacological properties and therapeutic use.
1984,
Pubmed
Feng,
Antisense oligodeoxynucleotides directed against Kv1.5 mRNA specifically inhibit ultrarapid delayed rectifier K+ current in cultured adult human atrial myocytes.
1997,
Pubmed
Fischer,
Acute and subacute effects of the selective serotonin-noradrenaline reuptake inhibitor duloxetine on cardiac hERG channels.
2013,
Pubmed
,
Xenbase
Fischer,
Inhibition of cardiac Kv1.5 and Kv4.3 potassium channels by the class Ia anti-arrhythmic ajmaline: mode of action.
2013,
Pubmed
,
Xenbase
Hüneke,
Effects of volatile anesthetics on cardiac ion channels.
2004,
Pubmed
Kanto,
Midazolam: the first water-soluble benzodiazepine. Pharmacology, pharmacokinetics and efficacy in insomnia and anesthesia.
1985,
Pubmed
Kulka,
Methohexital vs midazolam/flumazenil anaesthesia during laryngoscopy under jet ventilation.
1990,
Pubmed
Li,
Evidence for two components of delayed rectifier K+ current in human ventricular myocytes.
1996,
Pubmed
López-Izquierdo,
Thiopental inhibits function of different inward rectifying potassium channel isoforms by a similar mechanism.
2010,
Pubmed
Madeja,
Follicular tissues reduce drug effects on ion channels in oocytes of Xenopus laevis.
1997,
Pubmed
,
Xenbase
Michaloudis,
The effects of midazolam or propofol followed by suxamethonium on the QT interval in humans.
1996,
Pubmed
Miró,
Cessation of paroxysmal atrial fibrillation during acute intravenous propofol administration.
2000,
Pubmed
Morani,
General anaesthesia for external electrical cardioversion of atrial fibrillation: experience of an exclusively cardiological procedural management.
2010,
Pubmed
Nerbonne,
Molecular basis of functional voltage-gated K+ channel diversity in the mammalian myocardium.
2000,
Pubmed
Nonaka,
Mechanism of the negative inotropic effect of midazolam and diazepam in cultured foetal mouse cardiac myocytes.
1997,
Pubmed
Nordt,
Midazolam: a review of therapeutic uses and toxicity.
1997,
Pubmed
Persson,
Pharmacokinetics of midazolam in total i.v. anaesthesia.
1987,
Pubmed
Reves,
Midazolam: pharmacology and uses.
1985,
Pubmed
Scholz,
In vitro modulation of HERG channels by organochlorine solvent trichlormethane as potential explanation for proarrhythmic effects of chloroform.
2006,
Pubmed
,
Xenbase
Scholz,
Anticholinergic antiparkinson drug orphenadrine inhibits HERG channels: block attenuation by mutations of the pore residues Y652 or F656.
2007,
Pubmed
,
Xenbase
So,
Effects of midazolam on ion currents and membrane potential in differentiated motor neuron-like NSC-34 and NG108-15 cells.
2014,
Pubmed
Staikou,
Impact of anaesthetic drugs and adjuvants on ECG markers of torsadogenicity.
2014,
Pubmed
Study,
Diazepam and (--)-pentobarbital: fluctuation analysis reveals different mechanisms for potentiation of gamma-aminobutyric acid responses in cultured central neurons.
1981,
Pubmed
Thummel,
Oral first-pass elimination of midazolam involves both gastrointestinal and hepatic CYP3A-mediated metabolism.
1996,
Pubmed
Tibbs,
HCN1 channels as targets for anesthetic and nonanesthetic propofol analogs in the amelioration of mechanical and thermal hyperalgesia in a mouse model of neuropathic pain.
2013,
Pubmed
,
Xenbase
Wandel,
Midazolam is metabolized by at least three different cytochrome P450 enzymes.
1994,
Pubmed
Wettwer,
Role of IKur in controlling action potential shape and contractility in the human atrium: influence of chronic atrial fibrillation.
2004,
Pubmed
Wutzler,
Deep sedation during catheter ablation for atrial fibrillation in elderly patients.
2013,
Pubmed
Wutzler,
Minimal and deep sedation during ablation of ventricular tachycardia.
2014,
Pubmed
Yamakage,
Inhibitory effects of diazepam and midazolam on Ca2+ and K+ channels in canine tracheal smooth muscle cells.
1999,
Pubmed
Zitron,
QTc prolongation by grapefruit juice and its potential pharmacological basis: HERG channel blockade by flavonoids.
2005,
Pubmed
,
Xenbase
